Tip:
Highlight text to annotate it
X
Each day of the 7th International AIDS
Society Conference on *** Pathogenesis,
Treatment and Prevention in
Kuala Lumpur, Malaysia we'll be talking
with Dr. Carl Dieffenbach from the
National Institutes of Health. Here are the
highlights from Day 1.
Dr. Dieffenbach, I am excited to talk to
you from the International AIDS
conference in Malaysia. Sir, the opening
session just closed. Can you share some
highlights from that opening session.
Sure. It’s great to talk to you too Miguel.
Steve Deeks from the University of
California San Francisco spoke today
about the long term treatment of *** and
a new strategy. Basically, taking it on
as a, as a chronic disease. And this kind
of approach could lead to improvements
for everybody who is affected by ***
around the globe, if this kind of a new
policy and approach was implemented.
Additionally, a second major event
occurred here today with the W.H.O.
rolling out their new treatment guidelines.
Essentially, bringing their treatment
guidelines of everybody under 500, CB 4
count, under 500, being recommended to
go on therapy. Additionally there were
other populations of pregnant women,
people with Hepatitis B, tuberculosis and
people living discordant couples which are
recommended to get immediate therapy.
Those were the major highlights from
today’s session.
Well thank you so much, Sir and we are
going to be talking to you each day from
the conference. As you reflect on the
conference as a whole, is there some
messages that you would like to share
with those who will be following you this
week who are providing *** services in
the United States.
I think that one of the most important
things that came out of today’s meeting
that is relevant to the United States is the
sort of normalization or the integration of
continuity across the globe of who should
have access to therapy. And we are now
at a situation where twenty six million
people with these new guidelines
are eligible for treatment in the United States
This reinforces the need for,
in the United States,
us to work toward addressing
the *** treatment cascade,
starting with significant improvement in
how we test, how we link to care, how we
retain in care and how we maintain
people’s adherence to it. That was one of
the major messages that Dr. Deeks
brought forward is the importance of the
adherence and delivery of safe and
effective and durable
antiretroviral therapy.
Well thank you so much. I look forward to
talking to you on Day 2 of the conference.
This is Miguel Gomez with AIDS.gov.
Thank you Sir.
For more information on the conference
visit www.ias2013.org. And, for more
information about federal *** programs,
visit AIDS.gov.